Publicacions en què col·labora amb Miguel Xavier Fernandes (16)

2024

  1. Coumarin-azasugar-benzyl conjugates as non-neurotoxic dual inhibitors of butyrylcholinesterase and cancer cell growth

    Organic & biomolecular chemistry, Vol. 22, Núm. 17, pp. 3425-3438

2023

  1. Conformationally Restricted Glycoconjugates Derived from Arylsulfonamides and Coumarins: New Families of Tumour-Associated Carbonic Anhydrase Inhibitors

    International Journal of Molecular Sciences, Vol. 24, Núm. 11

  2. Investigation of the enantioselectivity of acetylcholinesterase and butyrylcholinesterase upon inhibition by tacrine-iminosugar heterodimers

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 38, Núm. 1, pp. 349-360

2022

  1. 2-Aminobenzoxazole-appended coumarins as potent and selective inhibitors of tumour-associated carbonic anhydrases

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 37, Núm. 1, pp. 168-177

  2. A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors

    Frontiers in Pharmacology, Vol. 13

  3. A hybrid of 1-deoxynojirimycin and benzotriazole induces preferential inhibition of butyrylcholinesterase (BuChE) over acetylcholinesterase (AChE)

    Journal of enzyme inhibition and medicinal chemistry, Vol. 37, Núm. 1, pp. 2395-2402

  4. Carbohydrate-derived bicyclic selenazolines as new dual inhibitors (cholinesterases/OGA) against Alzheimer's disease

    Bioorganic Chemistry, Vol. 127

  5. Squaramide-Tethered Sulfonamides and Coumarins: Synthesis, Inhibition of Tumor-Associated CAs IX and XII and Docking Simulations

    International Journal of Molecular Sciences, Vol. 23, Núm. 14

2021

  1. Tuning the activity of iminosugars: novel N-alkylated deoxynojirimycin derivatives as strong BuChE inhibitors

    Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 36, Núm. 1, pp. 138-146

2020

  1. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells

    Investigational New Drugs, Vol. 38, Núm. 3, pp. 584-598

2019

  1. Selenocoumarins as new multitarget antiproliferative agents: Synthesis, biological evaluation and in silico calculations

    European Journal of Medicinal Chemistry, Vol. 179, pp. 493-501

2018

  1. Anti-Proliferative 1,4-Dihydropyridine and Pyridine Derivatives Synthesized through a Catalyst-Free, One-Pot Multi-Component Reaction

    ChemistrySelect, Vol. 3, Núm. 43, pp. 12163-12168

2017

  1. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells

    European Journal of Pharmaceutical Sciences, Vol. 105, pp. 159-168

2015

  1. Synthesis and identification of unprecedented selective inhibitors of CK1ε

    European Journal of Medicinal Chemistry, Vol. 96, pp. 308-317

2013

  1. Generation of artificial neural networks models in anticancer study

    Neural Computing and Applications, Vol. 23, Núm. 3-4, pp. 577-582

  2. Molecular docking studies of the interaction between propargylic enol ethers and human DNA topoisomerase IIα

    Bioorganic and Medicinal Chemistry Letters, Vol. 23, Núm. 19, pp. 5382-5384